Pod Insights Talking Wealth Podcast: Stock Market Trading and Investing Education | Wealth Creation | Expert Share Market Analysis ASX Healthcare Sector Stock Opportunities About this episode This week on Talking Wealth, Janine examines the Australian and US Healthcare sectors, unloved ASX stocks, and focuses on a Pharma stock with a recent US approval. The Healthcare Sector is an area all investors need to keep an eye on. The key is not to buy on news. Instead it’s better to get the timing right to be rewarded.
Transcript 0:01 Speaker 00 This podcast is brought to you by Wealth Within, a global leader in stock market education. For more information on our courses, head over to wealthwithin.com.au. Please note that the information in this podcast should not be considered personal financial advice. Enjoy.
0:20 Speaker 01 Hello, my name's Janine Cox, Senior Analyst at Wealth Within. Today, I'm going to be talking about the healthcare sector, not just in Australia but in the US, touching on that, and then leading into a discussion on a very interesting healthcare stock, one that you probably want to pay particular attention to. So, without further ado, the reason that I raised this one is because I was reading something by a stockhead, and they talked about Telx Pharmaceuticals and how the price surged after the US Centers for Medicare and Medicaid Services granted transitional pass-through status for its prostate cancer
1:01 Speaker 01 imaging product, GOS-Alix. This means that US hospitals can get reimbursed more easily, a crucial catalyst for adoption. So, I thought it was really interesting because we've been saying for some time that pharmaceutical stocks or biotech stocks are the ones that you need to keep your eye on. There's a whole transition going on in the healthcare space. You might be wondering, why is healthcare down when it has historically been such a defensive sector, and also one for the boom time? We've seen lots of healthcare stocks over time that have been incredibly strong and have gone through this transition where
1:44 Speaker 01 they're being sold off right now. And some of the big names are CSL, we've seen Sonic Healthcare, Ramsay, lots of different stocks have fallen away, the bigger ones, but there are huge opportunities in some of the smaller healthcare stocks, even middle-of-the-road healthcare stocks. Still, a couple of the big ones, provided they move with technology and the take-up of that technology. stays, then those stocks will continue to be strong. ResMed's a good example. Cochlea's another one. Cochlea's pulled back as well. But these ones offer significant runs or gains to be made when markets return to the bull phase,
2:27 Speaker 01 which, if you've watched our show recently and listened to many of our podcasts, you would have heard our view on that and where we're expecting the market to go. But really, there are times in the market where it's more critical than others to be keeping an eye on the sectors and what particular sectors are doing in the market. The challenge in Australia is because our healthcare sector, the weight is so concentrated on a number of big stocks, that these stocks tend to have a more significant impact on the formation of the healthcare sector chart. So therefore, it can be skewed. And therefore, if you were looking at that and you were seeing that it was falling,
3:10 Speaker 01 you'd be thinking, well, that means, you know, wealth within, say, if something's falling, stay away from it. We're not trying to catch a falling knife. However, there can be stocks within the subsectors within these sectors that might actually be setting up to do much better. I looked at what the US healthcare sector is doing and compared it to our own. So I'm just, I'm just looking at a healthcare sector chart at the moment. This is the Australian one. The code is X H J. If you're interested. Now, obviously, this is dominated by the big health stock CSL.
3:50 Speaker 01 We've seen CSL fall away recently. It may actually be pretty close to finding support for the next run. And looking at the healthcare sector, we can see that it's just been sideways since 2020. So since Covid. Hit, we can see it made, actually made its high just before COVID in February 2020, but it's never, since then, it's not been able to get back up to that high and push through. So this is a really protracted sideways move that we're seeing on, in this space. Cause you've got to think, this is four years, or five years really now, of a sideways consolidation. And how often do you see that happen?
4:31 Speaker 01 Well, it's interesting to look back over the healthcare space and see, when was the last time that we saw this sort of action happen? And we did see it in October 2007. So when, when the GFC hit, we saw the healthcare space pull back, but nowhere near to the degree that other stocks experienced the declines. And we saw more or less a sideways transition that occurred all the way into 2011. Let's think about that. It, it's pretty much five years that we saw this whole activity take place. And we're seeing a repeat of that, although the pattern that we're seeing is quite different to what we observed back then.
5:15 Speaker 01 But it's timing that's so important. And when I think about the timing and what happened back around the time of the GFC and how long it took. So when the GFC hit, obviously the market fell into a low in 2009. We can all look back on a chart and see that now. Then it made a recovery, but it really struggled through two, even into 2011, early 2012, or through part of 2012. And before it then really got going. And I can see that unfolding on the healthcare space right back to 2012. We can see that at that point, it started to get some momentum going.
5:56 Speaker 01 How long could it take potentially for us to see the same sort of activity unfold? Well, that's a big question, but one that we still need to really consider because when we're looking at what happened in the healthcare space, it tended to follow the angle of the trend for quite some time before it then broke below it. And you'd think that maybe you would find support on the angle of the trend. We often see stocks and markets do the same thing. And, and that's what I'm looking at now with the healthcare space. It's still hanging around the angle of that, of the healthcare sector, still hanging around the angle of the longer term trend.
6:36 Speaker 01 A fall below the low in October 2023 obviously is going to change things significantly, but it could also signify that the bottom's not too far away for the healthcare sector. Now, when I went and had a look at what's happening in the US market, it was quite different looking at what's happening in the US market. So in there, we've seen the code for the healthcare sector in the US, I think, is, I'll just be guessing, but just Google S and P 500 healthcare sector, that will bring it up for you under Google Finance, you'll see it. And you can see a sideways activity that's happened there from around 2021.
7:20 Speaker 02 Hey, podcasters, you're here for a reason, to become a more confident and profitable trader. And you can achieve this because it's all about having the right knowledge. We have a course that will suit you and improve the profits you take from the market. Curious to learn more? Head over to Wealth Within and check out our trading courses.
7:41 Speaker 01 It's, it really was sideways all the way through until around late 2023, when it started to take off again. It got to a new all time high in September 2024, so last year, and has since been declining. Now, the strongest level that I can see under all of that is still yet to be tested. So right now, it's actually come off a low, looks like it's trying to test that low to see if there's a bit of traction.
8:11 Speaker 01 But it still could fall further, that's the risk right now. And we can see that with our own sector. So I guess things to look for, if you're looking at healthcare stocks and the bigger ones, for instance, is to check to see whether they're finding support on particular levels. Now, if you've studied our course, you'll know how to identify the difference between just any natural support and resistance level, which could appear to you to be the strongest level. But until you've actually done the analysis, you won't know what the strongest level is. You've got to actually look at a confluence of analysis to tell you whether the stock has a high probability of turning. So this is using price, pattern
8:53 Speaker 01 and time, not just a natural level on a chart which may actually provide support. But what happens if it falls through it? How do you know where the next level is going to be? It could fall at the next level. It looks like it met resistance in the past, but it may fall below. It may come down to that. Test it and then you look for an entry and you think that it's going to turn. But to someone who's a technical analyst who's done all their work, may have already found that there's a level just below that where the market turns. So this could potentially help in even understanding if you did get into it and everything, you ticked all the boxes, it all looked fine, but there's always other levels below. The important thing is to understand which ones have the highest
9:35 Speaker 01 probability. And then if it does break, the nearest low to the one that you've entered, you know roughly how far it's likely to fall before it'll find support again. And that just means that the next time that it takes off, it could be even stronger than what you originally predicted it to be. It could be the better trade that you're about to take after that one. So never give up on a stock completely, just because it's taken out below nearest to where you've purchased. If you had to sell and your stop loss triggered, you just wait patiently for the next one, because there will be other opportunities. Now, I'm talking about more liquid stocks rather than penny stocks, which, you know, you can see some penny stocks continue to fall until then they're delisted. They no
10:20 Speaker 01 longer operate on the marketplace. And that's where buying at that end of the market can be higher risk. What's the probability of a much bigger stock being delisted because it's falling? It's much, much lower. So therefore, you're just eliminating one of those risks. If you list all the risks related to entering and how you're mitigating those risks, that can be a way to develop a plan as well for your trading, regardless of what the timeframe is that you're trading on.
10:51 Speaker 01 Now, in looking through what's going on in the healthcare space, we can see that there's been big changes in the US. And you know, this has been happening over a long period of time. So I'd looked at an article by P W C and they talk about by 2035, healthcare will be proactive, automated, robot-enabled and accessible wherever life happens. I mean, this sounds all very futuristic. There are some incredible stocks out there in biopharma and that are using AI already. There are pharmaceuticals, um, medical related stocks that are doing just that. And we've got to keep our eye peeled to the stocks that are really making advances.
11:36 Speaker 01 So we all think about, you know, the terrible things happening around the world and the wars that are going on. And the, the, the robots, if you like, that are assisting in to enable all of that. But there are also robots that can fly. Just say someone needed an organ in a hurry and, you know, instead of taking it by road, it could be flown by drone and, and, you know, have a much better chance of getting to its destination quicker when it's needed. But all of the things like that, life-saving medication could be flown around to patients who are at home. There's this shift to trying to keep patients at home where possible.
12:19 Speaker 01 Well, you know, there's always been, I guess, people tell me there's always been this issue with, you know, they go to hospital and they try, they get pushed out really quickly. Oh, you went in for this operation? Yes. And then, um, I was only in for a couple of days. Oh, really? That sounds like a major operation. How come they let you go home so soon? Um, that's a whole different discussion again. But what we're looking at here is a big shift in what's happening. And P W C are suggesting just to really explore the future of healthcare and how it might look in the years to come. And therefore, what technologies and what companies will be leading the space or leading the charge. Um, you know, we could have robots that are actually the caregivers in the future
13:04 Speaker 01 and assisting people in the home. I mean, I don't know how the elderly would feel about that, though. There's a whole shift. The young people might like that, but um there's some elderly people I know that would not not be happy about that. Um, so, you know, I mentioned before about the drones and, um, you know, imagine that you get a call, um, answer you, open your door because there's a drone there with you, with your prescription. So you, instead of having to go out to the pharmacy and pick it up, um, it's not posted in the mail, you're actually getting it on the day within potentially half an hour or an hour of when you you order it. Wouldn't that be nice?
13:45 Speaker 01 And there are also diagnostic equipment that's going to be um at a whole new level and where we even can conceive right now. We see it in movies and and the the way that they're handling this um looks quite amazing and and we're looking at what technology is going to bring to all of this. So there's a whole potential shift coming and we need to be prepared for it, especially when you're investing in this in the stock market and there are going to be big opportunities. Now, the healthcare industry in the U S accounts for over five trillion in annual spending and is expected to continue growing faster than, and this is comes from McKinsey and
14:28 Speaker 01 Company report, than the GDP over the next decade is far growing faster than the GDP of the U S. Despite facing challenges such as high inflation and labour shortages, the industry plays a significant role in the economy, influencing job markets and contributing to overall economic stability. So when I looked at what's happening um on the health front in Australia and the consolidation we're seeing in our market at the moment and similar sort of consolidation that we've seen, although not as bearish, if you like, as our market, but there is nonetheless a consolidation in the U S tech sector, then I thought it was important to really go through and and have a good look at where things are headed.
15:13 Speaker 01 Now, a company that came up, um, that was on the radar, as I said, that came up in one of um Stockhead's articles was Talix.
15:25 Speaker 02 Hey podcasters, are you looking for a practical and easy way to profit consistently from the stock market so you take control of your investments? Get Dale's bestselling book, How to Beat the Managed Funds by 20% for free, just pay shipping. It's packed with powerful, simple strategies that will give you the confidence and know-how to beat the managed funds by 20%. Visit the shop on the Wealth Within website and secure your copy today.
15:53 Speaker 01 Now, Talex Pharmaceuticals is an ISX company, TLX is the code, is a global biopharmaceutical company engaged in the development and commercialisation of targeted therapeutic and diagnostic radio pharmaceuticals, along with supporting medical technologies. It's headquartered in Melbourne, actually, in Australia, and Talex maintains strategic international operations across the United States, Brazil, Canada, Europe, that includes Belgium, Switzerland and Japan, so far-reaching exposure. So I guess when you're looking for these biopharmaceuticals, you've got to look for the, obviously the products or the technology that they've got, where does, what does that service?
16:37 Speaker 01 Is there a demand for that? And think about where these stocks are going, because some of them are on the lower end of the liquidity spectrum, they may not suit your portfolio. If your portfolio is set up and you've got a designed portfolio that you've chosen and you've specified what stocks are going to be included, don't ruin that by putting things in there that are just not suited to it. You might decide to create another portfolio that you have, and you might have four or five stocks, but remember, it's about risk management, you've got to be careful about how much you put into that, and it may be 10% of your overall capital that you're going
17:19 Speaker 01 to allocate to running portfolios or the stock market, a small portion of that, you might break up into four or five stocks that you look and have a different strategy on those, maybe a different timeframe that you're setting on those, it may be more of a shorter term growth opportunity. But in saying that, some of these stocks can turn into more medium term and and much bigger returns than what you might originally envisage. So it's about how do you tell and at what point do you decide to move it from short term thinking to more medium term. There is no announcement that's got to tell you that because an announcement could come out.
18:03 Speaker 01 It sounds fantastic and the share price falls. How many times have you seen that? This is more about having that understanding of what's forming on the chart. And what does it really mean to the medium term trajectory? And this is not just about taking our word for it. This is about you developing the skills so that you can actually understand and make those decisions yourself and have the confidence to do it. It's when you don't have the confidence to do it that you're then seeking other people's opinions on that. So you want to put yourself in a position of power that you can make those decisions and that you're responsible for the way that your portfolio evolves.
18:43 Speaker 01 I mean, you know, while stocks are going up and they're strong, you can be, you know, thinking, oh, well, this is too easy. I'll just take some recommendations off the Australian Stock Market Weekly Show. Well, when I say recommendations, they're just our analysis of a stock that we think could be good. We haven't said exactly where you should buy it. You've got to make that decision yourself. But it's where what we think looks good and what what we would caution you on if it went the other way. So there's a lot involved in, you know, what could potentially form on the right hand side of the chart from the time that we talk about it, um, you know, over months, weeks or months from there. Sometimes stocks will go up really quickly. Sometimes they may take a lot longer to go up.
19:27 Speaker 01 And at other times, they might fall first before they then rise. So it's it's about, you know, having the line in the sand and. And always having that confirmation and having a strategy. Now, if you're, if you're listening to people talk about stocks online and then you're going and making a decision without having proper rules, you're not going to know how to get out of them. And you don't want to be investing your funds and then relying on someone to tell you when to exit. This is about, if you're really wanting to trade yourself, then it's about making sure that you've got the knowledge and skills. To me, it's a no brainer to do that. But anyway, enough about that. Let's go in and have a look at Talix. As I said, this stock is probably, it has a few similar companies
20:11 Speaker 01 in the, in the healthcare space, according to Market Index, which I've just read the definition out from their website, but MSB and CU6 are other ones listed there. It's quite a big company so far. 2025 year to date, it's down 33.44%, and one year it's down 20.8%. So it versus the ASX 200 is down 29%. So therefore, any news that comes out about these companies could potentially push the share price forward. The trick is not to respond on news. Don't jump in or get FOMO.
20:52 Speaker 01 The, the challenge for you is to make sure that you've actually got the ability to say, no, I don't think it's ready yet, or yep, it's ready and I can go and tick all the boxes. So the news about this stock was that, and I've got this also on a website called Capital Brief, and I'm not vouching for this or any other website that I've read the information of. It's just a Google search. Talix Pharmaceuticals was a top performer on the ASX 200 in morning trade after this announcement. That's what happened. So what happens is the share price goes up significantly and a lot of people try to jump in and follow it based on that. That's what we're cautioning you not to do.
21:35 Speaker 01 So what's happened here is after the US Centers for Medicare and Medicaid Services granted the transitional pass-through payment status for biotech's prostate cancer imaging agent, GOSLIX. Now, this transitional pass-through payment thing is really interesting. So it actually puts, the pass-through approval refers to the process of granting approval for a request or document to proceed after it's passed through a series of checks or reviews. So this is like jumping a hurdle, really, for this company. Now, in legal terms, it can refer to the approval process for legislative or regulatory approvals, ensuring that the necessary conditions are met before law or regulation is enacted.
22:21 Speaker 01 But with the, on the medical side, it actually means that these payments are actually mechanisms in the US healthcare system that provide additional payments for new medical devices, drugs and biologicals that meet specific eligibility criteria. And these payments are intended to encourage the use of newly FDA-approved medical devices and to boost Medicare patients' access to innovative therapies. They're part of a Medicare outpatient perspective payment system and are designed to be temporary payments until Medicare has sufficient claims data to set a permanent rate.
23:05 Speaker 01 Payments are calculated based on the cost of the device or whatever it is exceeding the amount included. Now, I won't go into any more of that, but this is a really big deal. I've read something else on Magnolia Market Access website, again, not putting my stamp on any of these, but just it came up in a Google search, that Medicare pays for hospital outpatient services under the, oh, hang on, additional payments for therapies. So there's all of these.
23:37 Speaker 01 Transitional pass-through payments, a valuable tool for manufacturers looking to maximise market access and product adoption in the early stages of a product's life cycle. By securing pass-through status, companies can accelerate market entry, support a strong pricing strategy and gather essential real-world data to inform longer-term reinvestment strategies. It helps lay the groundwork for future success in the competitive healthcare market. This is huge. Now, what did that mean to the share price? That's the really interesting thing. Did it cause the share price to double or do
24:16 Speaker 01 anything amazing like that? Obviously, there are additional steps in this because otherwise you would think that the share price would just rocket away. So what I want to do now is go and have a look at what's happened to the stock.
24:33 Speaker 01 The code is TLX. Now, what we've seen is an all-time high occurred in February 2025. This is a stock clearly impacted by Trump's tariffs. It had a dramatic fall and we've seen it, the depths of where it fell. So if you think about the high, it was 31.97 at that all-time high when everything was roses at the start of the year. It then fell to 13.32. So it's fallen more than 50, almost, well, around 60% or close to, it's fallen
25:11 Speaker 01 more than 50% as part of this. But the news, the recent news pushed the share price up and it went back up to about $18. So from 13.32 to $18, not bad. But this is in one week we've seen a big turnaround in the share price. Is that enough to suggest that this is sustainable? No. There's a long road ahead. Lots of pharmaceutical companies...
25:40 Speaker 01 Get into really good positions in the marketplace and then things for whatever reason go the other way. The share price doesn't necessarily unfold how the market or investors think it will. So, right now, there is something to get quietly excited about, but is this the end of the fall? Well, let's have a look at what the technical analysis indicates. So, I've marked in it really important level of support on the stock, first of all. And yes, while we actually show these levels, it is the easiest thing to add to the chart. So that's part of the reason why on the show, you will see lots of horizontal lines. But as you've also seen, often stocks don't stop there, they keep
26:24 Speaker 01 going. So it's not to say that Talex is actually going to stop at this level. It may. But we don't have proof yet. We don't have enough evidence to suggest this. So if I add a few more things to my chart, it reveals a whole lot more. So I'm seeing that there's a potential for this stock to get to $20 in the short term. So, short-term traders, it's actually closed down too. It got to $18, profit takers came in, they've pulled it back to $16.30. So what's that telling you? You know, they're not prepared to really commit to it at this stage. So if a move to $20 is still not the hurdle that we want
27:07 Speaker 01 to see, it's just the start. Because the angle of the trend is always your friend. It's the trend is your friend scenario is definitely the most important thing.
27:19 Speaker 02 Hey, podcasters. Are you curious to learn how you can gain more confidence with your trading? Check out the Australian Stock Market Show on YouTube every Tuesday night from 7 to 8 p.m. Discover how you can become a more successful trader and take your trading to another level. Get your most burning questions answered with Dale and Janine. We look forward to you joining us.
27:44 Speaker 01 What we have been able to identify is having a look at the trend and the way that it's unfolded, it has come back to a very important point on the overall trend. Because this stock, we've seen this stock go from incredible levels all the way up above $30. Back in 2022, it was trading at $9. So it's got the potential to do great things, but whether it repeats it again, being a stock at a, you know, a smaller stock in the market, and so one of the bigger ones that we perhaps could follow, that's the real question. And a really strong level for this stock is back down at that $8 level
28:24 Speaker 01 that I mentioned, $8 or $10. I would have ideally liked to see it come back to around that $8, $10 mark and then for the turnaround to happen. But maybe I'm just trying to make things a bit too perfect because, I mean, $12 is important as well. So it could be somewhere between 10, 9, or around 9 and $12 that we see it come back to if it does not hold, if the angle of the overall trend up doesn't hold the stock in position. Now, some of you who have done our course, you will be putting lines on your chart, having a look at this, just wanting to see what, you know, where the stock's unfolded. But to think about it, to visualize this, we've had one, two, three, four, five, six, seven
29:07 Speaker 01 months down, if you can imagine that, and the stock has fallen more than 50%, almost around probably closer to 60% of, you know, its all time high, which is a massive move in that short amount of time and shows that you can't just buy and hold these stocks, specifically these pharma stocks. You've got to have proper rules. And there were some really good rules with this one. Dale's book, How to Beat the Managed Funds by 20%. It tells you what to do with trend lines, how to apply them, you know, how to buy and sell using them.
29:49 Speaker 01 It's a critical tool to have and to understand really well. Now, if we look at the, we can go to a weekly chart and have a look at what the stock did as it accelerated to its high. It kept this beautiful trend and, and once you get on one of these trends on, on a farmer or healthcare stock, they can go for quite a while, as we've seen with CSL. So in looking at the way that this stock might unfold in future, if it follows a similar sort of angle to what it's done in the past, then we could very well see it back above 2150 or thereabouts. If it gets through the angle of that downtrend. So that's the really important thing here.
30:34 Speaker 01 Don't try to get in too early for stocks like these on a bounce off that bottom when you don't know whether that bounce is actually finished. So it could come all the way back to the recent low. So the recent low was actually, I've got here 14, 14, I think 13 dollars, around 13 dollars. It could actually come back from 16 dollars to around that low. It's made a gap up, it's coming back to try to fill it. So that's really important because it may just be, you know, a temporary pullback before the next run happens as the market sort of reassesses where the stock's at. Volume was really good, but then volume has been high as part of the selling.
31:18 Speaker 01 So we've seen high volume all the way through the, the selling point from around July 2025 when it gapped down. And I don't know the reasons why it gapped down at that time. You can go and look at announcements and have a look around the 23rd of July and see what came out then. And then what followed after that, because it has gapped down quite a few times since then. It shows that, you know, you can quickly go from a stock that's being at 25 dollars to a stock that's 13 dollars, you know. And, and it doesn't, it only takes a few weeks or a month or so sometimes for that to happen on these shares. So you better hang on to your hat, that's all I can say, unless you've got some really
32:00 Speaker 01 good rules to manage it. So, looking ahead now, Telx could be one of the ones to watch, but you know, there are other healthcare stocks as well that could be on your radar, but it's about picking the ones that you think have the greatest potential and lining up all of the things that have done. So you might have a shortlist, yep, this is what I found on this particular stock, write, write them down, what are the pros and cons to taking a trade and do the pros outweigh the cons? And at this point, the cons outweigh the pros, given that while the news may be great, fundamentally it might be a good story, technically it's not yet proven, it's too early. Don't try and get into these things
32:41 Speaker 01 as the early, because the profit tags will come in and they'll just take you down and you'll be stopped out. That's quite often what we see.
32:51 Speaker 01 All right, I think that's probably all I've got on this stock today, Telx Pharmaceuticals and the healthcare space, but keep an eye on both, on the sector as well as these stocks, because when the sector eventually turns around, some of these stocks will go even faster. I wish you all the best with your trading, take care. I'm Janine Cox, Senior Analyst. Bye for now.
33:14 Speaker 00 Thanks for listening to our Talking Wealth podcast. For more exclusive content covering topics like the stock market, real estate, business, performance and psychology and more, check out talkingwealth.com today.
Previous 8 Hidden ASX Resource Stocks to Buy Before they Takeoff! Next Legends of Trading: Gann, Dow, and Livermore Page updated November 6, 2026 · transcript and summary are machine-generated